Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for China Pharma Holdings (CPHI) over the last 11 years, with Q2 2025 value amounting to $1.3 million.

  • China Pharma Holdings' Non-Current Debt fell 593.23% to $1.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.3 million, marking a year-over-year decrease of 593.23%. This contributed to the annual value of $1.4 million for FY2024, which is 147.04% down from last year.
  • Latest data reveals that China Pharma Holdings reported Non-Current Debt of $1.3 million as of Q2 2025, which was down 593.23% from $1.4 million recorded in Q1 2025.
  • In the past 5 years, China Pharma Holdings' Non-Current Debt ranged from a high of $1.4 million in Q3 2024 and a low of $325072.0 during Q2 2021
  • Its 4-year average for Non-Current Debt is $1.2 million, with a median of $1.4 million in 2023.
  • Its Non-Current Debt has fluctuated over the past 5 years, first plummeted by 8356.18% in 2021, then soared by 246.02% in 2024.
  • China Pharma Holdings' Non-Current Debt (Quarter) stood at $325072.0 in 2021, then soared by 334.33% to $1.4 million in 2023, then dropped by 1.47% to $1.4 million in 2024, then dropped by 5.12% to $1.3 million in 2025.
  • Its Non-Current Debt stands at $1.3 million for Q2 2025, versus $1.4 million for Q1 2025 and $1.4 million for Q4 2024.